SCHEMBL16420669

SCHEMBL16420669

CC(C)[S+]([O-])c1ccc(-c2cncc(-c3nnc(CCNC(=O)OC(C)(C)C)o3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.56
▸ HTT P42858 4/20 0.43
▸ MAPT P10636 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ LMNA P02545 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ HPGD P15428 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ ALDH1A1 P00352 6/20 0.40
▸ TSHR P16473 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ XBP1 P17861 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16424877 0.86 ATR (0.76) ATR
SCHEMBL17826197 0.85 ATR (0.57) ATRHTTMAPTTDP1POLB
SCHEMBL16489031 0.75 ATR (0.52) ATRCYP3A4
SCHEMBL16070030 0.72 ATR (0.77) ATR
SCHEMBL16420621 0.72 ATR (0.58) ATR
SCHEMBL16420498 0.71 ATR (0.53) ATRMAPTTDP1POLBLMNA
SCHEMBL16420620 0.70 ATR (0.43) ATRMAPTPOLBKDM4EHPGD
SCHEMBL12419604 0.70 HTT (0.55) ATRHTTMAPTTDP1POLB
SCHEMBL17826171 0.70 ATR (0.41) ATRSMN1; SMN2
SCHEMBL16420495 0.69 ATR (0.37) ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2018-06-21 — — US disclosed
US-9365557-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 — — US disclosed
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885HTT 2185/4885MAPT 2916/4885
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885HTT 2185/4885MAPT 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback